SutroVax rais­es $64M with plans to chal­lenge Pfiz­er’s megablock­buster Pre­vnar 13 for the heavy­weight ti­tle in vac­cines

When SutroVax was spun out of Sutro about four years ago, the biotech took along a con­ju­ga­tion plat­form that was re­pur­posed for de­vel­op­ing a new …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA